Abstract
Prostate cancer is one of the most common types of cancer in men worldwide. The incidence of prostate cancer continuously increases (improvement in diagnostic methods) while the mortality rate remains stationary.
In the diagnosis of prostate cancer, prostate specific antigen (PSA) has a privileged position as the main serum marker. It is an organ-specific but not tumor-specific marker.
Several other parameters have been derived from PSA to increase its sensitivity and specificity. PSA is expected to be used in the future as part of the planned screening programme.